Clovis Oncology

Clovis down after discontinuing rucaparib bladder cancer trial
BioCentury
Fri, 04/12/19 - 11:48 pm
Clovis Oncology
Rubraca
bladder cancer
Early pancreatic cancer data give Clovis a new path in PARP market
Biopharma Dive
Tue, 04/2/19 - 04:22 pm
pancreatic cancer
Clovis Oncology
AstraZeneca
PARP inhibitors
AACR
Rubraca
Lynparza
Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover
Yahoo/Zacks.com
Wed, 02/27/19 - 10:53 am
Clovis Oncology
earnings
Want to buy Clovis? Step up. ‘Everybody knows where to find me,’ CEO says
Fierce Pharma
Fri, 01/11/19 - 08:12 pm
M&A
Patrick Mahaffy
Pharma CEOs
Clovis Oncology
JPMHC 2019
JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3
Biopharma Dive
Thu, 01/10/19 - 12:31 pm
Editas
CRISPR
GSK
Tesaro
Clovis Oncology
M&A
AbbVie
JPMHC 2019
Clovis dips as Tesaro reveals more details of its acquisition
Biopharma Dive
Wed, 12/19/18 - 12:33 am
Clovis Oncology
Tesaro
M&A
Could These Be the Next 2 Biotech Buyouts?
Motley Fool
Sun, 12/9/18 - 03:41 pm
biotech
M&A
Agios Pharmaceuticals
Clovis Oncology
Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca
CP Wire
Tue, 12/4/18 - 09:36 am
Clovis Oncology
Europe
Rubraca
Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca
Tue, 12/4/18 - 09:13 am
Clovis Oncology
Rubraca
7 drugs that raised eyebrows in Q3
Biopharma Dive
Thu, 11/15/18 - 11:50 pm
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
PARP makers search for a way to break through
Biopharma Dive
Fri, 11/9/18 - 12:08 am
AstraZeneca
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
Here's Why Clovis Oncology Stock Dropped a Whopping 60.4% in October
Motley Fool
Tue, 11/6/18 - 11:50 pm
Clovis Oncology
Rubraca
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
Sat, 10/27/18 - 12:16 pm
BrainStorm Cell Therapeutics
Allergan
Pfizer
Clovis Oncology
Acorda Therapeutics
Takeda
Agios Pharmaceuticals
Shire
Teva Pharmaceutical
AbbVie
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
Wed, 10/24/18 - 12:38 pm
PARP inhibitors
physicians
Zejula
Rubraca
Lynparza
AstraZeneca
Merck
Tesaro
Clovis Oncology
Clovis' Rubraca leads to 44% ORR in Phase II for CRPC
BioCentury
Sat, 10/20/18 - 11:07 pm
Clovis Oncology
Rubraca
rucaparib
metastatic castration-resistant prostate cancer
Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca for Metastatic Castration Resistant Prostate Cancer
CP Wire
Tue, 10/2/18 - 09:55 am
Clovis Oncology
Rubraca
Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca for Metastatic Castration Resistant Prostate Cancer
Tue, 10/2/18 - 09:49 am
Clovis Oncology
Rubraca
Clovis Oncology to Pay the SEC $20 Million for Misleading Investors
BioSpace
Wed, 09/19/18 - 11:29 am
Clovis Oncology
SEC
investors
lung cancer
rociletinib
Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer
CP Wire
Wed, 08/8/18 - 09:35 am
Clovis Oncology
clinical trials
Bristol-Myers Squibb
Opdivo
ovarian cancer
Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer
Wed, 08/8/18 - 09:01 am
Clovis Oncology
Rubraca
Opdivo
ovarian cancer

Pages